Undiagnosed light chain systemic amyloidosis: does it matter to anesthesiologists? -a case report- by �씠醫낆꽍 et al.
Light chain systemic amyloidosis is rare but may accompany laryngeal or pulmonary involvement, which may increase 
the risk in airway management. We present a case of a patient planned for resection of cervical epidural mass. The patient 
had face and neck ecchymoses and purpuras with an unknown cause. Mask ventilation and intubation were successful, but 
the operation was cancelled to evaluate bleeding from facial skin lesions. A diagnosis of light chain systemic amyloidosis 
prompted evaluation of involvement of other organs and treatment. This case shows the importance of preoperative evalu-
ation and careful airway management in patients with systemic amyloidosis. (Korean J Anesthesiol 2013; 65: 453-455)
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CC
Systemic amyloidosis is rare and usually underdiagnosed. 
Misfolded protein fibrils deposit into tissues in various organs. 
Systemic amyloidosis has subtypes of light chain (AL) amyloi-
dosis, amyloid A (AA) amyloidosis, dialysis-related amyloidosis, 
hereditary amyloidosis such as familial amyloidosis with poly-
neuropathy, cardiac or renal amyloidosis, and organ specific 
amyloidosis such as Alzheimer disease, cardiac, laryngeal, or 
pulmonary amyloidosis [1]. AL amyloidosis is the most com-
mon subtype and is caused by deposition of protein derived 
from immunoglobulin light chain fragments. Laryngeal or 
pulmonary involvement requires attention by the anesthetist to 
airway management in the perioperative period [2,3]. Therefore, 
diagnosis of amyloidosis for any surgical patient should prompt 
an evaluation of the involvement of other organs, including the 
airway, before anesthetic induction and complete preparation 
for difficult airway management. We present a case of systemic 
amyloidosis patient whose diagnosis occurred subsequent to 
anesthesia. 
Case Report
A 63-year-old male, 159 cm in height and 70 kg in weight, 
was scheduled to undergo resection of cervical epidural mass. 
The patient had a medical history of well-controlled hyperten-
sion and old healed pulmonary tuberculosis. The patient had 
facial and neck purpuras and ecchymoses, whose cause could 
not be identified at a private dermatologic clinic. Blood test re-
sults concerning platelet count, prothrombin time and activated 
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partial thrombosplastin time were normal.
General anesthesia was induced with propofol 100 mg and 
remifentanil 0.5 μg/kg/min. Rocuronium 50 mg was admin-
istrated to facilitate tracheal intubation. Anesthesia was main-
tained with 6 vol% desflurane with 50% O2 in air, remifentanil, 
and rocuromium. After a change from a supine to a prone posi-
tion, bleeding from the lacerated facial purpuras was recognized 
while identifying head position on a Mayfield headrest. Swollen 
purpuras and eyeballs hyperemia were evident. The operation 
was canceled in order to evaluate the facial lesions and the pa-
tient was transported to the postanesthetic care unit when fully 
conscious. 
Skin biopsy from the facial lesions (Fig. 1) and serum free 
light chain assay were performed during the stay at the general 
ward, and resulted in the diagnosis of systemic amyloidosis of 
monoclonal gammopathy with lambda type. Multiple myeloma, 
which usually accompanies systemic amyloidosis, was excluded 
after bone marrow biopsy and immunoprotein measurement of 
serum and urine. 
The patient had complained of dyspnea since post-anesthesia 
day 16. Bilateral pleural effusion and interstitial pulmonary 
edema were identified by high resolution chest computed to-
mography. Pulmonary function test revealed moderate degree 
of chronic obstructive pulmonary disease. Cervical magnetic 
resonance imaging taken 48 days after the anesthesia showed 
spontaneous resolution of the epidural mass. Post-anesthetic 
echocardiograph showed thickened myocardium, which was not 
confirmatory of cardiac amyloidosis. According to abdominal 
ultrasound, there was no hepatomegaly or splenomegaly. Symp-
toms and signs suggesting the involvement of other organs, such 
as renal, neurologic, and hematologic abnormalities, were not 
observed. Treatment with chemotherapy and auto-peripheral 
blood stem cell transplantation was planned.
Discussion
Systemic amyloidosis is caused by tissue deposition of insolu-
ble misfolded protein fibrils. AL amyloidosis, the most common 
type of systemic amyloidosis, is characterized by deposition of 
protein derived from immunoglobulin light chain fragments. AL 
amyloidosis is caused by the monoclonal expression of plasma 
cells in the bone marrow that secrete a clonal immunoglobulin 
light chain of kappa or lambda type, which deposits as amyloid 
fibrils in tissues [1]. 
Clinical manifestations are determined by the type of amyloid 
and the distribution of deposition. AL amyloidosis syndromes 
include renal involvement with nephrotic range proteinuria or 
renal failure; cardiomyopathy with thick-walled heart, low volt-
age on electrocardiogram, and pericardial and pleural effusions; 
cholestatic hepatopathy; peripheral neuropathy and autonomic 
neuropathy; infiltration of soft tissues, of which macroglossia is 
a pathognomonic findings; and purpura, including periorbital 
ecchymoses due to capillary involvement and/or clotting factor 
deficiency [4]. 
Any patient presenting with cardiomyopathy with preserved 
systolic function, heavy albuminuria, an unexplained sensorim-
otor peripheral neuropathy, hepatomegaly, or atypical mono-
clonal gammopathy of undetermined significance or myeloma 
should be suspected of having AL amyloidosis [5]. But, patients 
may have nonspecific symptoms like dyspnea, fatigue, weight 
loss, edema, paresthesia, diarrhea or constipation due to auto-
nomic dysfunction, dry mouth, or hoarseness, which usually 
present in more common disorders.
Once amyloid is identified by biopsy, further evaluation for 
systemic disease and organ involvement should include creati-
nine, 24 hour urine total protein, electrocardiogram, echocar-
diogram, and alkaline phosphatase. Cardiac biomarkers like 
troponin and N-terminal pro-brain natriuretic peptide should 
be measured because the extent of cardiac involvement is im-
portant for determining prognosis [6].
All patients diagnosed as systemic AL amyloidosis need ther-
apy. Early diagnosis provides much broader therapeutic options 
and enables reversal of organ damage. Treatment is aimed to 
eliminate misfolded amyloidogenic light chains, minimize treat-
ment toxicity, and support the targeted organ function. Treat-
ment should be individualized based on age, organ dysfunc-
tion, and regimen toxicity. Therapeutic options are high-dose 
melphalan/autologous stem cell transplantation, corticosteroids, 
alkylating agents, immunomodulatory drugs, and proteasome 
inhibitors [5]. 
Fig. 1. Ecchymoses and purpuras around the lips and on the eyelids and 
neck.
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Cardiac amyloidosis is caused by extracellular deposition 
of amyloid in the endomyocardium, conduction pathway or 
coronary vessels. Symptoms may vary from atypical symptoms 
like fatigue, lightheadedness, and pedal edema to arrhythmia or 
ischemic symptoms, and even heart failure. Cardiac amyloidosis 
can be diagnosed directly by endomyocardial biopsy or indi-
rectly by echocardiography. Evaluating cardiac involvement is 
important to determine the prognosis of systemic amyloidosis. 
There was no typical finding indicative of cardiac amyloidosis 
like granular sparkling appearance of myocardium in an echo-
cardiography that is performed preoperatively. Interpretation of 
an echocardiography performed after the diagnosis of AL amy-
loidosis includes thickened and speckled myocardium, without 
obvious cardiac involvement. Presently, there was an incomplete 
left bundle branch block on preoperative electrocardiogram; 
however, this finding and echocardiographic result complicated 
the diagnostic exclusion of cardiac amyloidosis. Laryngeal amy-
loidosis is rare but may be caused by either systemic or localized 
amyloidosis. Patients most commonly present with hoarseness, 
but may also have stridor, dyspnea, or dysphagia. Systemic in-
volvement should be ruled out after the laryngeal lesion is con-
firmed as amyloidosis by tissue biopsy. Treatment of localized 
laryngeal amyloidosis is surgical resection and the long-term 
outcome is excellent. A case of anesthetic management with a 
patient with laryngeal amyloidosis has been reported [7].
Pulmonary amyloidosis includes tracheobronchial infiltra-
tion, persistent pleural effusions, parenchymal nodules, and, 
rarely, pulmonary hypertension. Tracheobronchial infiltration 
may cause hoarseness, stridor, airway obstruction, and dyspha-
gia. One case report described the extensive involvement in 
the entire laryngo-tracheo-bronchial tree [2]. In the report, a 
53-year-old man had been followed up for five years for systemic 
amyloidosis involving the larynx, trachea, and bronchi. Ventila-
tion was impossible with airway obstruction after intubation, 
which was relieved by extensive debridement of tissues in the 
lower trachea using a rigid bronchoscope under supraglottic jet 
ventilation. 
Precaution is imperative when a patient with laryngeal or tra-
cheal amyloidosis involvement during anesthetic induction. The 
mass may cause airway obstruction, increasing the risk during 
intubation. Imaging is required before induction to evaluate the 
extent of obstruction. A differential diagnosis is needed, such as 
a malignant tumor of the airway. Unfortunately, the systematic 
amyloidosis was not diagnosed in our patient prior to anesthetic 
induction. If amyloidosis were diagnosed beforehand, evalua-
tion for airway involvement should have been performed before 
anesthesia. Preoperative airway assessment is recommended to 
avoid any complications such as airway obstruction due to mass, 
desaturation, and even death [3]. Maintaining spontaneous 
ventilation without muscle relaxant may be considered as ap-
propriate technique during induction of patients with airway in-
volvement. It is recommended that fiberoptic bronchoscopy and 
tracheostomy be prepared in case of difficult airway. Also, vari-
ous sizes of tracheal tubes should be prepared. Airway obstruc-
tion can be a serious problem. The patient should be monitored 
in the intensive care unit postoperatively because obstruction 
can occur at emergence and extubation.
In our case, relevant symptoms that would definitively rule 
out systemic amyloidosis were typical purpura and ecchymoses 
in face and neck, without obvious coagulation defect. Purpura in 
a periorbital distribution in amyloidosis patients, also described 
as raccoon eyes, is quite characteristic of AL amyloidosis. Hem-
orrhagic lesions as a mucocutaneous manifestation are caused 
by deposition of amyloid in and around vessels, resulting in in-
creased vascular fragility. Presently, it was very fortunate that the 
patient with just skin lesions did not have involvement of other 
critical organs, including the heart, kidney and especially the 
larynx. 
Systemic amyloidosis especially involving the airway is rare 
but anesthesiologists should recognize the possibility during the 
perioperative period. Patient’s airway should be evaluated while 
formulating the anesthetic plan as well as the function of the 
involved organs, and provisions should be in place to manage 
airway difficulties.
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